ALNY Earnings Preview: Alnylam Q1 2026 on April 30

Alnylam Pharmaceuticals, Inc. (ALNY) will report first-quarter 2026 earnings on April 30 after market close. Analysts expect $1.43 earnings per share and $1.12 billion in revenue. The biotech company has faced significant headwinds, with shares down 24% year-to-date despite a strong long-term track record. Investors will scrutinize product sales, pipeline progress, and cash burn as the RNAi therapeutics leader navigates a challenging market environment. Understanding these estimates and historical performance patterns is critical for evaluating ALNY’s near-term direction.

Earnings Estimates and Historical Performance

Analysts project ALNY will deliver $1.43 EPS and $1.12 billion in revenue for Q1 2026. This represents a notable shift from recent quarters, where the company has shown mixed results.

Recent Earnings Track Record

Looking at the last four quarters, ALNY has demonstrated inconsistent performance. In Q4 2025 (reported February 12), the company beat EPS estimates by delivering $0.82 actual versus $1.16 estimated, missing expectations. Revenue came in at $1.097 billion versus $1.149 billion estimated, also falling short. The Q3 2025 report showed $0.32 EPS versus -$0.54 estimated, a significant beat, with revenue at $773.7 million versus $662.9 million estimated. This pattern suggests ALNY has struggled with consistency, beating on one metric while missing on another.

Estimate Trend Analysis

The current $1.43 EPS estimate sits between recent actual results, suggesting analysts are moderating expectations after the Q4 miss. Revenue guidance of $1.12 billion aligns closely with recent quarterly performance, indicating stabilization expectations. The company’s ability to meet these revised estimates will be crucial for investor confidence.

What Investors Should Watch

ALNY’s earnings report will reveal critical details about product commercialization and pipeline advancement in the competitive RNAi therapeutics space.

Product Sales Performance

Key marketed products include ONPATTRO (patisiran) for hereditary transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria. Investors should monitor whether these franchises are gaining market traction or facing competitive pressure. The company’s gross margin of 81.7% on marketed products provides substantial room for profitability if sales accelerate.

Pipeline and Development Updates

ALNY has multiple programs in clinical development, including vutrisiran for ATTR amyloidosis in phase 3 trials, Zilebesiran for hypertension, and ALN-HSD for NASH. Any clinical trial updates, regulatory interactions, or partnership announcements could significantly impact the stock. The company’s $22 billion market cap reflects expectations for these pipeline assets to drive future growth.

Cash Position and Burn Rate

With $21.99 cash per share, ALNY maintains a solid balance sheet. However, operating cash flow growth of 64% year-over-year suggests the company is investing heavily in R&D and commercialization. Investors should assess whether cash burn remains sustainable and if the company needs additional financing.

Technical and Valuation Context

ALNY trades at a significant premium to historical averages, raising questions about valuation sustainability.

Valuation Metrics

The stock trades at a P/E ratio of 130.22, substantially elevated compared to biotech peers and the broader market. The price-to-sales ratio of 10.95 also reflects premium pricing. These multiples suggest investors are pricing in significant future growth. If earnings miss expectations or guidance disappoints, the stock could face downward pressure given the valuation cushion is limited.

Technical Weakness

Technical indicators show concerning signals ahead of earnings. The RSI of 39.98 indicates oversold conditions, while the MACD histogram of -1.99 suggests negative momentum. The stock has declined 2.07% in the last day and 24% year-to-date, creating a challenging backdrop for the earnings announcement. A beat could trigger a relief rally, while a miss could accelerate selling.

Analyst Consensus and Meyka Grade

Wall Street maintains a constructive stance on ALNY despite recent weakness, with strong analyst support.

Analyst Ratings

The consensus rating shows 13 Buy ratings, 1 Hold, and 0 Sell ratings, reflecting broad optimism about the company’s long-term prospects. This strong support suggests analysts believe current weakness is temporary and that ALNY’s pipeline justifies premium valuations. However, consensus can shift quickly if earnings disappoint or guidance weakens.

Meyka AI Grade

Meyka AI rates ALNY with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B+ rating suggests ALNY is a solid performer relative to peers but faces near-term headwinds. The grade is not guaranteed, and investors should conduct their own research before making investment decisions.

Final Thoughts

Alnylam Pharmaceuticals reports earnings on April 30 with $1.43 EPS and $1.12 billion revenue expected. The company’s inconsistent performance and elevated valuation create a high bar for positive surprise. Investors should monitor product sales momentum, pipeline updates, and cash runway. Despite 13 analyst Buy ratings, near-term execution is critical. A beat could trigger a relief rally given oversold conditions, while a miss risks accelerated selling. The earnings report will determine whether ALNY’s premium valuation holds or faces further downside.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.